Sugi Predict

Sugi Predict / Compounds / SCHEMBL19202664

SCHEMBL19202664

SCHEMBL19202664

Cc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)nc(-c2ccc(Oc3ccccn3)cc2)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 3/20 0.48
▸ PRMT5 O14744 2/20 0.45
▸ BTK Q06187 3/20 0.45
▸ GPR119 Q8TDV5 2/20 0.44
▸ HTT P42858 2/20 0.43
▸ HPGD P15428 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CRHBP P24387 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19202665 0.87 TP53 (0.44) TNK2PRMT5BTKGPR119HTT
SCHEMBL19202666 0.83 BTK (0.54) TNK2PRMT5BTKGPR119HTT
SCHEMBL19203187 0.82 CHEK2 (0.49) PRMT5GPR119HTTHPGDKDM4E
SCHEMBL19202375 0.81 GPR119 (0.44) TNK2PRMT5BTKGPR119HTT
SCHEMBL31615913 0.79 GPR119 (0.55) GPR119HTTPDE10A
SCHEMBL19203215 0.77 BTK (0.46) TNK2BTK
SCHEMBL16598006 0.75 BTK (0.71) TNK2PRMT5BTKHTTHPGD
SCHEMBL19203190 0.73 KDM4E (0.47) GPR119HTTHPGDKDM4EALDH1A1
SCHEMBL4080053 0.73 GPR119 (0.65) GPR119KDM4EMAPT
SCHEMBL30469398 0.73 GPR119 (0.65) GPR119KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336755-B2 Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2019-07-02 — — US disclosed
US-20190016721-A1 FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2019-01-17 — — US disclosed
WO-2017128917-A1 PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES 北京诺诚健华医药科技有限公司 2017-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336755-B2 Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases BTK, SYK, JAK1 TNK2 328/4885PRMT5 645/4885BTK 1/4885
US-20190016721-A1 FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES BTK, SYK, JAK1 TNK2 328/4885PRMT5 645/4885BTK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.